Voss-affiliated group reports ~5.0% stake in Teladoc
Teladoc Health (Common Stock) ownership disclosure: a group led by Voss entities and Travis W. Cocke reports beneficial ownership stakes in the issuer.
Rhea-AI Filing Summary
Teladoc Health (Common Stock) ownership disclosure: a group led by Voss entities and Travis W. Cocke reports beneficial ownership stakes in the issuer. The filing lists specific holdings by entity, including 9,025,722 shares held by Voss Capital/Cocke-affiliated accounts and related entities and references 180,513,087 shares outstanding as of April 23, 2026.
The schedule states that Voss Value Master Fund beneficially owns 1,803,606 shares (including 700,000 shares underlying currently exercisable call options), Voss Value-Oriented Special Situations Fund owns 200,000 shares, and Voss GP may be deemed to beneficially own both fund holdings. The filing attributes approximately 5.00% beneficial ownership to Voss Capital and to Travis W. Cocke on an aggregate basis, and smaller percentages to the other named reporting persons.
Positive
- None.
Negative
- None.
Insights
Filing reports concentrated stake by Voss-affiliated entities totaling roughly 5.0% of Teladoc.
The schedule lists explicit share counts and percentages: 9,025,722 shares associated with Voss Capital/Cocke entities and 180,513,087 shares outstanding as of April 23, 2026, producing the disclosed ~5.00% ownership figures. The filing also notes 700,000 shares underlying exercisable call options included in the fund totals.
Key dependencies include the issuer's outstanding share count cited from its Form 10-Q; any change in that baseline would alter percentage calculations. Subsequent filings may update positions or percentages.
Schedule 13G mechanics: aggregation and attribution across funds, GP, manager, and individual are explicitly disclosed.
The filing attributes holdings to five reporting persons and explains how Voss GP (general partner) and Voss Capital (investment manager) may be deemed beneficial owners of fund positions and managed accounts. The report follows the required disclosure format, including sole voting/dispositive power line items and citizenship/place of organization for each filer.
Material follow-ups would appear in amendments if holdings change above reporting thresholds; the filing provides signatures and dates of execution on 06/22/2026.
Key Figures
Key Terms
beneficially owned regulatory
call options currently exercisable financial
sole dispositive power regulatory
general partner legal
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Voss Capital report in Teladoc (TDOC)?
Why are multiple Voss entities listed separately in the Schedule 13G?
Does the filing disclose exercisable options included in reported holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.